Baseline demographics and clinical characteristics of a subgroup of older patients in the POLARIX study
| Characteristic∗ . | Patients aged ≥60 y . | Patients aged ≥65 y . | Patients aged ≥70 y . | Patients aged ≥75 y . | ||||
|---|---|---|---|---|---|---|---|---|
| Pola-R-CHP (n = 311) . | R-CHOP (n = 318) . | Pola-R-CHP (n = 231) . | R-CHOP (n = 236) . | Pola-R-CHP (n = 141) . | R-CHOP (n = 143) . | Pola-R-CHP (n = 60) . | R-CHOP (n = 60) . | |
| Age, median (range), y | 69 (60-80) | 69 (60-80) | 71 (65-80) | 71 (65-80) | 74 (70-80) | 73 (70-80) | 77 (75-80) | 77 (75-80) |
| Age group, y | ||||||||
| ≥60 to <65 | 80 (25.7) | 82 (25.8) | — | — | — | — | — | — |
| ≥65 to <70 | 90 (28.9) | 93 (29.2) | 90 (39.0) | 93 (39.4) | — | — | — | — |
| ≥70 to <75 | 81 (26.0) | 83 (26.1) | 81 (35.1) | 83 (35.2) | 81 (57.4) | 83 (58.0) | — | — |
| ≥75 | 60 (19.3) | 60 (18.9) | 60 (26.0) | 60 (25.4) | 60 (42.6) | 60 (42.0) | 60 (100) | 60 (100) |
| Sex | ||||||||
| Male | 161 (51.8) | 168 (52.8) | 115 (49.8) | 123 (52.1) | 65 (46.1) | 70 (49.0) | 29 (48.3) | 30 (50.0) |
| Female | 150 (48.2) | 150 (47.2) | 116 (50.2) | 113 (47.9) | 76 (53.9) | 73 (51.0) | 31 (51.7) | 30 (50.0) |
| Ann Arbor stage | ||||||||
| I-II | 42 (13.5) | 47 (14.8) | 27 (11.7) | 34 (14.4) | 17 (12.1) | 22 (15.4) | 10 (16.7) | 12 (20.0) |
| III-IV | 269 (86.5) | 271 (85.2) | 204 (88.3) | 202 (85.6) | 124 (87.9) | 121 (84.6) | 50 (83.3) | 48 (80.0) |
| Extranodal sites | ||||||||
| 0-1 | 180 (57.9) | 178 (56.0) | 125 (54.1) | 133 (56.4) | 77 (54.6) | 77 (53.8) | 35 (58.3) | 31 (51.7) |
| ≥2 | 131 (42.1) | 140 (44.0) | 106 (45.9) | 103 (43.6) | 64 (45.4) | 66 (46.2) | 25 (41.7) | 29 (48.3) |
| Bulky disease (≥7.5 cm) | 128 (41.2) | 126 (39.6) | 98 (42.4) | 94 (39.8) | 59 (41.8) | 60 (42.0) | 22 (36.7) | 24 (40.0) |
| ECOG performance status, n | 311 | 317 | 231 | 235 | 141 | 142 | 60 | 60 |
| 0-1 | 266 (85.5) | 270 (84.9) | 194 (84.0) | 199 (84.7) | 119 (84.4) | 122 (86.0) | 50 (83.3) | 49 (81.7) |
| 2 | 45 (14.5) | 47 (14.8) | 37 (16.0) | 36 (15.3) | 22 (15.6) | 20 (14.0) | 10 (16.7) | 11 (18.3) |
| IPI score, n (%) | ||||||||
| 2 | 99 (31.8) | 103 (32.4) | 66 (28.6) | 72 (30.5) | 42 (29.8) | 44 (30.8) | 17 (28.3) | 20 (33.3) |
| 3-5 | 211 (67.8) | 215 (69.1) | 165 (71.4) | 164 (69.5) | 99 (70.2) | 99 (69.2) | 43 (71.7) | 40 (66.7) |
| Cell of origin, n† | 237 | 252 | 175 | 187 | 108 | 112 | 42 | 45 |
| ABC | 79 (33.3) | 105 (41.7) | 55 (31.4) | 74 (39.6) | 33 (30.6) | 45 (40.2) | 12 (28.6) | 19 (42.2) |
| GCB | 131 (55.3) | 114 (45.2) | 99 (56.6) | 85 (45.5) | 65 (60.2) | 50 (44.7) | 24 (57.1) | 23 (51.1) |
| Unclassified | 27 (11.4) | 33 (13.1) | 21 (12.0) | 28 (15.0) | 10 (9.3) | 17 (15.2) | 6 (14.3) | 3 (6.7) |
| Unknown | 74 | 66 | 56 | 49 | 33 | 31 | 18 | 15 |
| Double expressor lymphoma‡ | 104 (40.9) | 119 (45.4) | 80 (42.3) | 89 (45.4) | 48 (42.1) | 55 (46.2) | 18 (40.9) | 24 (49.0) |
| Double-/triple-hit lymphoma§ | 21 (9.0) | 14 (5.7) | 15 (8.7) | 9 (4.9) | 8 (7.6) | 7 (6.1) | 2 (4.8) | 4 (8.7) |
| Characteristic∗ . | Patients aged ≥60 y . | Patients aged ≥65 y . | Patients aged ≥70 y . | Patients aged ≥75 y . | ||||
|---|---|---|---|---|---|---|---|---|
| Pola-R-CHP (n = 311) . | R-CHOP (n = 318) . | Pola-R-CHP (n = 231) . | R-CHOP (n = 236) . | Pola-R-CHP (n = 141) . | R-CHOP (n = 143) . | Pola-R-CHP (n = 60) . | R-CHOP (n = 60) . | |
| Age, median (range), y | 69 (60-80) | 69 (60-80) | 71 (65-80) | 71 (65-80) | 74 (70-80) | 73 (70-80) | 77 (75-80) | 77 (75-80) |
| Age group, y | ||||||||
| ≥60 to <65 | 80 (25.7) | 82 (25.8) | — | — | — | — | — | — |
| ≥65 to <70 | 90 (28.9) | 93 (29.2) | 90 (39.0) | 93 (39.4) | — | — | — | — |
| ≥70 to <75 | 81 (26.0) | 83 (26.1) | 81 (35.1) | 83 (35.2) | 81 (57.4) | 83 (58.0) | — | — |
| ≥75 | 60 (19.3) | 60 (18.9) | 60 (26.0) | 60 (25.4) | 60 (42.6) | 60 (42.0) | 60 (100) | 60 (100) |
| Sex | ||||||||
| Male | 161 (51.8) | 168 (52.8) | 115 (49.8) | 123 (52.1) | 65 (46.1) | 70 (49.0) | 29 (48.3) | 30 (50.0) |
| Female | 150 (48.2) | 150 (47.2) | 116 (50.2) | 113 (47.9) | 76 (53.9) | 73 (51.0) | 31 (51.7) | 30 (50.0) |
| Ann Arbor stage | ||||||||
| I-II | 42 (13.5) | 47 (14.8) | 27 (11.7) | 34 (14.4) | 17 (12.1) | 22 (15.4) | 10 (16.7) | 12 (20.0) |
| III-IV | 269 (86.5) | 271 (85.2) | 204 (88.3) | 202 (85.6) | 124 (87.9) | 121 (84.6) | 50 (83.3) | 48 (80.0) |
| Extranodal sites | ||||||||
| 0-1 | 180 (57.9) | 178 (56.0) | 125 (54.1) | 133 (56.4) | 77 (54.6) | 77 (53.8) | 35 (58.3) | 31 (51.7) |
| ≥2 | 131 (42.1) | 140 (44.0) | 106 (45.9) | 103 (43.6) | 64 (45.4) | 66 (46.2) | 25 (41.7) | 29 (48.3) |
| Bulky disease (≥7.5 cm) | 128 (41.2) | 126 (39.6) | 98 (42.4) | 94 (39.8) | 59 (41.8) | 60 (42.0) | 22 (36.7) | 24 (40.0) |
| ECOG performance status, n | 311 | 317 | 231 | 235 | 141 | 142 | 60 | 60 |
| 0-1 | 266 (85.5) | 270 (84.9) | 194 (84.0) | 199 (84.7) | 119 (84.4) | 122 (86.0) | 50 (83.3) | 49 (81.7) |
| 2 | 45 (14.5) | 47 (14.8) | 37 (16.0) | 36 (15.3) | 22 (15.6) | 20 (14.0) | 10 (16.7) | 11 (18.3) |
| IPI score, n (%) | ||||||||
| 2 | 99 (31.8) | 103 (32.4) | 66 (28.6) | 72 (30.5) | 42 (29.8) | 44 (30.8) | 17 (28.3) | 20 (33.3) |
| 3-5 | 211 (67.8) | 215 (69.1) | 165 (71.4) | 164 (69.5) | 99 (70.2) | 99 (69.2) | 43 (71.7) | 40 (66.7) |
| Cell of origin, n† | 237 | 252 | 175 | 187 | 108 | 112 | 42 | 45 |
| ABC | 79 (33.3) | 105 (41.7) | 55 (31.4) | 74 (39.6) | 33 (30.6) | 45 (40.2) | 12 (28.6) | 19 (42.2) |
| GCB | 131 (55.3) | 114 (45.2) | 99 (56.6) | 85 (45.5) | 65 (60.2) | 50 (44.7) | 24 (57.1) | 23 (51.1) |
| Unclassified | 27 (11.4) | 33 (13.1) | 21 (12.0) | 28 (15.0) | 10 (9.3) | 17 (15.2) | 6 (14.3) | 3 (6.7) |
| Unknown | 74 | 66 | 56 | 49 | 33 | 31 | 18 | 15 |
| Double expressor lymphoma‡ | 104 (40.9) | 119 (45.4) | 80 (42.3) | 89 (45.4) | 48 (42.1) | 55 (46.2) | 18 (40.9) | 24 (49.0) |
| Double-/triple-hit lymphoma§ | 21 (9.0) | 14 (5.7) | 15 (8.7) | 9 (4.9) | 8 (7.6) | 7 (6.1) | 2 (4.8) | 4 (8.7) |
ABC, activated B cell; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B cell.
Data presented as n (%) unless otherwise specified. Percentages are based on the total older patient population, unless otherwise specified as an evaluable population.
In the Pola-R-CHP and R-CHOP arms, respective numbers of evaluable patients were 237 and 252 in patients aged ≥60 years, 175 and 187 in patients aged ≥65 years, 108 and 112 in patients aged ≥70 years, and 42 and 45 in patients aged ≥75 years.
In the Pola-R-CHP and R-CHOP arms, respective numbers of evaluable patients were 254 and 262 in patients aged ≥60 years, 189 and 196 in patients aged ≥65 years, 114 and 119 in patients aged ≥70 years, and 44 and 49 in patients aged ≥75 years.
In the Pola-R-CHP and R-CHOP arms, respective numbers of evaluable patients were 233 and 245 in patients aged ≥60 years, 172 and 185 in patients aged ≥65 years, 105 and 114 in patients aged ≥70 years, and 42 and 46 in patients aged ≥75 years.